Pathophysiology of atherosclerosis: Development, regression, restenosis

There is now a very large number of patients with coronary artery disease who have also undergone percutaneous interventions such as coronary angioplasty. Atherosclerosis and restenosis are two distinct pathologic processes with different underlying pathophysiologic mechanisms, different natural histories, different clinical presentations, and treatment strategies. Management strategies to target both processes are currently poorly applied in clinical practice. The development of integrated management strategies to target atherosclerosis, as well as restenosis in the post-procedural period remains a priority.

[1]  S. Schwartz.  Smooth muscle migration in atherosclerosis and restenosis. , 1997, The Journal of clinical investigation.

[2]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[3]  D. Holmes,et al.  Medical Therapy after Successful Percutaneous Coronary Revascularization , 1999, Annals of Internal Medicine.

[4]  F. Murad,et al.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Libby,et al.  The smooth muscle cell: sinner or saint in restenosis and the acute coronary syndromes? , 1998, Journal of the American College of Cardiology.

[6]  D. Harrison,et al.  Atherosclerosis Impairs Endothelium‐Dependent Vascular Relaxation to Acetylcholine and Thrombin in Primates , 1986, Circulation research.

[7]  M. Leon,et al.  Lipid-lowering therapy after coronary revascularization: the interventional cardiologist's perspective. , 1998, The American journal of cardiology.

[8]  E. Edelman,et al.  Hoop dreams. Stents without restenosis. , 1996, Circulation.

[9]  V. Fuster,et al.  Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. , 1994, Circulation.

[10]  P. Libby,et al.  Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. , 1996, The American journal of medicine.

[11]  D. Steinberg.  Antioxidants and atherosclerosis. A current assessment. , 1991, Circulation.

[12]  P. Libby,et al.  Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. , 1997, Circulation.

[13]  P. Serruys,et al.  A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. , 1999, European heart journal.

[14]  G. Condorelli,et al.  Activation of cAMP–PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury , 1997, Nature Medicine.

[15]  S. Schwartz.  Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. , 1997 .

[16]  R D Kamm,et al.  Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. , 1992, Circulation research.

[17]  C. Bauters,et al.  Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. , 1999, Journal of the American College of Cardiology.

[18]  R. Virmani,et al.  Pathology of acute and chronic coronary stenting in humans. , 1999, Circulation.

[19]  S. Zyzanski,et al.  Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. , 1998, Circulation.

[20]  J. Mehta,et al.  Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance. , 1990, Journal of the American College of Cardiology.

[21]  G. Davı̀,et al.  Thromboxane Biosynthesis, Neutrophil and Coagulative Activation in Type IIa Hypercholesterolemia , 1995, Thrombosis and Haemostasis.

[22]  N. Woolf,et al.  Cigarette smoking and platelet adhesion , 1984, Lancet.

[23]  D. Waters,et al.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.

[24]  M. Gimbrone.  Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. , 1995, The American journal of cardiology.

[25]  J. Liao,et al.  Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase (*) , 1995, The Journal of Biological Chemistry.

[26]  P. Hartigan,et al.  A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. , 1992, The New England journal of medicine.

[27]  B. Strauss,et al.  The extracellular matrix in balloon arterial injury: a novel target for restenosis prevention. , 1998, Progress in cardiovascular diseases.

[28]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[29]  M. Mann,et al.  Cell cycle progression: new therapeutic target for vascular proliferative disease. , 1998, Circulation.

[30]  U. Steinbrecher,et al.  Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. , 1987, The Journal of biological chemistry.

[31]  J. Tardif,et al.  Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. , 1999, Circulation.

[32]  S. Epstein,et al.  The basis of molecular strategies for treating coronary restenosis after angioplasty. , 1994, Journal of the American College of Cardiology.

[33]  M. Fishbein,et al.  A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. , 1991, Journal of the American College of Cardiology.

[34]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[35]  P. Libby.  Gene therapy of restenosis: promise and perils. , 1998, Circulation research.

[36]  E. Topol.  Coronary-artery stents--gauging, gorging, and gouging. , 1998, The New England journal of medicine.

[37]  E J Topol,et al.  Artery size, neointima, and remodeling: time for some standards. , 1998, Journal of the American College of Cardiology.

[38]  T. Kita,et al.  Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. , 1983, The New England journal of medicine.

[39]  E. Topol,et al.  Cell adhesion molecules in coronary artery disease. , 1994, Journal of the American College of Cardiology.

[40]  D. Harrison,et al.  Hypercholesterolemia increases endothelial superoxide anion production. , 1993, The Journal of clinical investigation.

[41]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[42]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[43]  E. Edelman.  Vessel size, antioxidants, and restenosis: never too small, not too little, but often too late. , 1998, Circulation.

[44]  V. Dzau,et al.  Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. , 1996, Circulation.

[45]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[46]  M. Leon,et al.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.

[47]  M. Gimbrone,et al.  Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype. , 1999, Molecular medicine today.

[48]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[49]  J. Tardif,et al.  Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes , 1998 .

[50]  V. de Waard,et al.  Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus. , 1999, Gene.

[51]  B. Risberg,et al.  Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. , 1994, Thrombosis research.

[52]  H. Daida,et al.  Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. , 1994, The American journal of cardiology.

[53]  S. Kaul,et al.  Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. , 1999, Circulation.

[54]  Schwartz Rs,et al.  Neointima and arterial injury: dogs, rats, pigs, and more. , 1994 .